Eight Reasons BioViva Will Dominate the Gene Therapy Industry
<p>Indispensability creates industry leaders. <strong>BioViva’s </strong>CMV gene delivery system does what other vectors cannot.</p>
<p>Current vectors provide scanty palettes and frayed brushes to prospective gene therapists, keeping the lion’s share of use cases outside their reach.</p>
<p>Gene therapy’s full potential can only be unleashed through large and redosable vectors like <strong>BioViva’s </strong>CMV.</p>
<p>It will be impossible to tackle complex diseases without large vectors. These are the most common and costly health issues in the developed world: Alzheimer’s, cancer, renal diseases, COPD, heart disease, diabetes, Parkinson’s, and, of course, aging itself.</p>
<p><a href="https://bioviva-science.medium.com/eight-reasons-bioviva-will-dominate-the-gene-therapy-industry-191c8ebef94c"><strong>Website</strong></a></p>